La Ténascine-X (TNX) est une glycoprotéine architecturale de la matrice extracellulaire. Outre ce rôle, la TNX est également considérée comme une protéine matricellulaire qui est capable de réguler le comportement de cellules normales et tumorales. Toutefois, aucun mécanisme moléculaire et cellulaire ne permettait d'expliquer les effets cellulaires de la TNX, avant notre étude. Au laboratoire, nous avons démontré que le domaine C-terminal de type fibrinogène (FBG) de la TNX était capable d'induire l'activation du Transforming Growth Factor (TGF) bêta latent. En effet, les trois isoformes du TGF bêta sont sécrétées sous la forme de complexes inactifs formés à partir de liaisons non covalentes entre le TGF bêta mature et son propeptide N-terminal LAP (Latency Associated Peptide). Nous avons montré que le domaine FBG de la TNX interagissait physiquement avec le TGF bêta latent, in vitro et in vivo, et induisait un changement de conformation du complexe latent, afin de permettre son activation en une molécule bioactive. De plus, nous avons identifié l'intégrine alpha11 bêta1 comme un récepteur membranaire pour la TNX et nous avons montré que cette intégrine était cruciale pour le processus d'activation du TGF bêta latent par le domaine FBG. Nous avons également démontré que les Méprines alpha et bêta deux protéases de la famille des astacines, pouvaient cliver la TNX, permettant ainsi de libérer des fragments contenant le domaine FBG, capables d'activer le TGF bêta latent. Enfin, nous avons entamé une étude de la pertinence biologique de l'activation du TGF bêta latent par la TNX in vivo en analysant la voie de signalisation du TGF bêta dans des souris déficientes ou non en TNX / Tenascin-X (TNX) is an architectural glycoprotein of the extracellular matrix. Beyond this role, TNX is also considered as a matricellular protein that is able to regulate the behavior of normal and tumor cells. However, no molecular and cellular mechanism has been described to explain TNX cellular effects before our study. In the laboratory, we showed that the C-terminal fibrinogen-like domain (FBG) of TNX was able to induce the latent transforming growth factor (TGF beta activation. Indeed, the three TGF beta isoforms are secreted as inactive complexes formed from non-covalent bonds between the mature TGF beta and its N-terminal propeptide, called LAP (Latency Associated Peptide). We showed that the FBG domain of TNX physically interacted with the latent TGF beta, in vitro and in vivo, and induced a conformational change of the latent complex to allow its activation into a bioactive molecule. Furthermore, we identified alpha1 beta1 integrin as a cell-surface receptor for TNX and showed that this integrin was crucial for the FBG-induced latent TGF beta activation. We also demonstrated that Meprins alpha and beta, two proteases belonging to the astacin family, could cleave the TNX, thereby releasing fragments containing the FBG domain capable of activating latent TGF beta. Finally, we have initiated a study regarding the biological relevance of latent TGF beta activation by TNX in vivo by analyzing the TGF beta signaling pathway in wild type or TNX-deficient mice

Le côlon des mammifères est colonisé d'environ 1013 bactéries. Si ce microbiote contribue au métabolisme, au développement et à la protection de l'organisme et représente une source massive d'antigènes. Il doit donc être compartimenté afin d'empêcher leur dissémination dans l'organisme où il pourrait être délétère. Lors de ma thèse, je me suis intéressé au rôle du Transforming Growth Factor beta (TGF-bêta, une cytokine fortement exprimée sous forme inactive au niveau de l'intestin des mammifères. Nous avons pu montrer que l'expression de l'intégrine alphav bêta 8par les lymphocytes T régulateurs (Treg) est essentielle à l'activation du TGF-bêta. Par ailleurs, mes travaux démontrent que deux protéines de la voie de signalisation du TGF-bêta, TIF-1gamma et SMAD4, contrôlent l'expression de l'IL-22 dans les cellules lymphocytaires innées de groupe 3 (ILC3) du côlon, responsable du maintien l'intégrité de la barrière intestinale empêchant l'entrée massive de bactéries et une suractivation des lymphocytes Th17 impliqués dans le développement spontané de cancers colorectaux. Ainsi, mes travaux de recherche ont permis de mettre en évidence le rôle clé du TGF-bêta dans le maintien de l'intégrité intestinale essentiel à la prévention du développement de cancers colorectaux induits spontanément par le microbiote / Mammalian colon harbors about 1013 bacteria. Although this microbiota contributes to metabolism, development and protection of the organism, it constitutes a huge source of antigens and must be compartmentalized in order to prevent intestinal bacteria dissemination in the organism that could be harmful for the host. During my PhD, I was interested in the role of Transforming Growth Factor beta (TGF-beta, a highly expressed cytokine and produced as an inactive form in mammalian gut. We showed that the expression of integrin alpha v beta 8by regulatory T cells (Treg) is essential to activate TGF-beta. Moreover, my work revealed that two proteins of the TGF-beta signaling pathway, TIF-1gamma and SMAD4, are responsible for the control of the expression of IL-22 within colonic group 3 Innate Lymphoid Cells (ILC3) which maintains the intestinal barrier integrity and prevents bacteria from entering and over-activation of Th17 cells involved in spontaneous colorectal cancer development. My work revealed a key role for TGF-beta in the maintenance of intestinal barrier-integrity essential to prevent spontaneous microbiota-induced colorectal cancer development

Morphogens are secreted signalling molecules that are expressed in restricted groups of cells within the developing tissue. From there, they are secreted and travel throughout the target field and form concentration gradients. These concentration profiles endow receiving cells with positional information. A number of experiments in Drosophila demonstrated that the morphogen Decapentaplegic (Dpp) forms activity gradients by inducing the expression of several target genes above distinct concentration thresholds at different distances from the source. This way, Dpp contributes to developmental fates in the target field such as the Drosophila wing disc. Although the tissue distribution as well as the actual shape and size of the Dpp morphogen concentration gradient has been visualized, the cell biological mechanisms through which the morphogen forms and maintains a gradient are still a subject of debate. Two hypotheses as to the dominant mechanism of movement have been proposed that can account for Dpp spreading throughout the Drosophila wing imaginal target tissue: extracellular diffusion and planar transcytosis, i. e. endocytosis and resecretion of the ligand that is thereby transported through the cells. Here, I present data indicating that implications of a theoreticalanalysis of Dpp spreading, where Dpp transport through the target tissue is solely based on extracellular diffusion taking into account receptor binding and subsequent internalization, are inconsistent with experimental results. By performing Fluorescence Recovery After Photobleaching (FRAP) experiments, I demonstrate a key role of Dynamin-mediated endocytosis for Dpp gradient formation. In addition, I show that most of GFP-Dpp traffics through endocytic compartments at the receiving epithelial cells, probably recycled through apical recycling endosomes (ARE). Finally, a Dpp recycling assay based on subcellular photouncage of ligand is presented to address specifically the Dpp recycling event at the receiving cells.

During cell communication, cells produce secreted signals termed morphogens, which traffic through the tissue until they are received by target, responding cells. Using the fruit fly Drosophila melanogaster as a model organism, I have studied transforming growth factor-beta (TGF-beta) signal from the secreting to the receiving cells in the developing wing epithelial cells and at the neuromuscular junctions. Cell culture studies have suggested that cells modulate morphogenetic signaling by expressing the receptors and secreting the ligand in spatially defined areas of the cell. Indeed, I have found that TGF-beta ligands, receptors and R-Smads show a polarized distribution both in the epithelial cells and at the synapses. My results indicate that the cellular junctions define a signaling domain within the plasma membrane, to which TGF-beta signaling machinery is targeted. In the context of epithelial cells, the junctions play a role in TGF-beta signaling regulation through their component beta-cat. A complex forms between beta-cat and the R-Smad Mad, but the mechanism by which beta-cat modulates signaling is not yet understood. At the synapse, the sub-cellular localization of TGF-beta pathway components indicates the occurrence of an anterograde signal. Moreover, my results suggest a scenario in which TGF-beta signaling is coupled with synaptic activity: quanta of growth factor, released upon neurostimulation together with neurotransmitter quanta, could modulate therefore the development and the function of the synapse.

Indiana University-Purdue University Indianapolis (IUPUI) / Pancreatic ductal adenocarcinoma (PDAC), which comprises 85% of pancreatic cancers, is the 4th leading cause of cancer death in the United States with a 5-year survival rate of 8%. While human PDACs (hPDACs) are hypovascular, they also overexpress a number of angiogenic growth factors and receptors. Additionally, the use of anti-angiogenic agents in murine models of PDAC leads to reduced tumor volume, tumor spread, and microvessel density (MVD), and improved survival. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful in hPDAC. On the other hand, pancreatic neuroendocrine tumors (PNETs) account for only 2% of pancreatic tumors, yet they are very vascular and classically angiogenic, respond to anti-angiogenic therapy, and confer a better prognosis than PDAC even in the metastatic setting. In an effort to compare and contrast the angiogenic transcriptomes of these two tumor types, we analyzed RNA-Sequencing (RNA-Seq) data from The Cancer Genome Atlas (TCGA) and found that a pro-angiogenic gene signature is present in 35% of PDACs and that it is mostly distinct from the angiogenic signature present in PNETs. The pro-angiogenic PDAC subgroup also exhibits a transcriptome that reflects active TGF-β signaling, less frequent SMAD4 inactivation than PDACs without the signature, and up-regulation of several pro-inflammatory genes, including members of JAK signaling pathways. Consequently, targeting the TGF-β receptor type-1 kinase with SB505124 and JAK1/2 with ruxolitinib blocks proliferative crosstalk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs). Additionally, treatment of the KRC (oncogenic Kras, homozygous deletion of Rb1) and KPC (oncogenic Kras, mutated Trp53) genetically engineered PDAC mouse models with ruxolitinib suppresses murine PDAC (mPDAC) progression only in the KRC model, which shows superior enrichment and differential expression of the human pro-angiogenic gene signature as compared to KPC tumors. These findings suggest that targeting both TGF-β and JAK signaling in the 35% of PDAC patients whose cancers exhibit an pro-angiogenic gene signature should be explored in a clinical trial.

It is now clear that human and animal exposure to estrogenic compound occurs through several sources. This include: i) naturally occurring endogenous estrogens, ii) exogenous or intentional estrogens for prophylactic (e.g. oral contraceptive) and therapeutic (e.g. as replacement therapy for ovulation in nulliparous women and in menopausal women, and in some men suffering from prostate cancer) purposes, iii) accidental via estrogenic chemical exposure (e.g. pesticides, industrial byproducts) and phytoestrogens (e.g. soybeans). It has long been recognized that estrogen, a female sex hormone, functions not only on the reproductive system, but also on various other systems including the immune system. Estrogens are thought to be of both physiologic and pathologic importance. Female in general, have better immune capabilities than males, a phenomenon attributed to the action of sex hormones on the immune system. There is also a female-gender bias in susceptibility to autoimmune diseases. Estrogens have been linked either directly or indirectly to the etiology and pathogenesis of various female-predominant autoimmune diseases. Estrogens have also been linked to the onset of cancer, and conditions where the immune system often malfunctions. Estrogen affects the functions of both B and T cells, possibly by regulating such factors as lymphokine gene expression and/or cellular death by apoptosis. However, the functioning of both B and T cells under the influence of long-term exposure to estrogen has not been fully understood. The primary aim of this thesis was to investigate the effect of long-term exposure to 17β-estradiol on lymphokine and bcl-2/fas (proto-oncogenes) mRNA expression. We evaluated the effects of estrogen on the expression of genes for lymphokines, which are essential for the immune response. It is hypothesized that estrogen may regulate the immune system by modifying the expression of lymphokine genes and/or genes that regulate apoptosis. The results demonstrated that long-term 17β-estradiol exposure reduced the viability of lymphocytes when compared to lymphocytes from placebo-treated mice. IL-2 and IFN-g mRNA was consistently higher in ConA-stimulated lymphocytes from estrogen-treated mice (P < 0.05). The mRNA for TGF-β₁ lymphokine was also increased but was not consistent at all time points of incubation. The expression of IL-4 mRNA was not noticeably affected by estrogen treatment of mice. Long-term exposure to 17β-estradiol appear to have some influence on the mRNA expression of proto-oncogenes fas and bcl-2 in splenic and thymic T lymphocytes. There was a trend of increased bcl-2 mRNA expression in estrogen-treated mice compared to placebo-treated mice, whereas the mRNA expression of fas gene appeared to be lower compared to controls. Overall, these findings suggest that 17β-estradiol may selectively influence lymphokine and proto-oncogene mRNA expression. These results suggest that the one mode of modulation of the immune response by 17β-estradiol may be through alterations in the lymphokine and proto-oncogene expression. Since estrogen-treatment markedly induces atrophy of the thymus and diminishes the cellularity of the lymphoid organs (e.g. Spleen), it became necessary to perform multiple assays on the same cells, particularly lymphokine and apoptosis gene expression. A secondary objective of this thesis was to investigate whether lymphocytes, which have undergone proliferation in Lympho-Pro™ assay (Alamar Blue assay), could be utilized for further analysis. In this regard, we found that a non-radioactive assay that utilizes Alamar Blue had significant advantages over the conventional ³H-thymidine incorporation assay. By using cells from estrogen and placebo-treated mice in the Alamar Blue assay, we found that this assay not only allowed determination of lymphocyte proliferation, but also the assessment of mRNA expression, cytogenetics, apoptosis and immunophenotyping of the same lymphocytes. / Master of Science

Indiana University-Purdue University Indianapolis (IUPUI) / Ovarian cancer (OC) is a lethal disease due to metastasis and chemoresistance. Our laboratory previously reported that tissue transglutaminase (TG2) is overexpressed in OC and enhances OC peritoneal metastasis. TG2 is a multifunctional protein which catalyzes Ca2+-dependent cross-linking of proteins. The purpose of this study was to explore the mechanism by which TG2 is upregulated in OC and its role in OC progression. We demonstrated that transforming growth factor (TGF)-β1 is secreted in the OC milieu and regulates the expression and function of TG2 primarily through the canonical Smad signaling pathway. Increased TG2 expression level correlates with a mesenchymal phenotype of OC cells, suggesting that TGF-β1 induced TG2 promotes epithelial-to-mesenchymal transition (EMT). TG2 induces EMT by negatively regulating E-cadherin expression. TG2 modulates E-cadherin transcriptional suppressor Zeb1 expression by activating NF-κB complex, which leads to increased cell invasiveness in vitro and tumor metastasis in vivo. The N-terminal fibronectin (FN) binding domain of TG2 (tTG 1-140), lacking both enzymatic and GTPase function, induced EMT in OC cells, suggesting the interaction with FN involved in EMT induction. A TGF-β receptor kinase inhibitor, SD-208, blocked TGF-β1 induced TG2 upregulation and EMT in vitro and tumor dissemination in vivo, which confirms the link between TGF-β1 and TG2 in EMT and tumor metastasis. TG2 expression was correlated with the number and size of self-renewing spheroids, the percentage of CD44+CD117+ ovarian cancer stem cells (CSCs) and with the expression level of stem cell specific transcriptional factors Nanog, Oct3/4, and Sox2. These data suggest that TG2 is an important player in the homeostasis of ovarian CSCs, which are critical for OC peritoneal metastasis and chemoresistance. TG2 expression was also increased in CSCs isolated from human ovarian tumors, confirming the implication of TG2 in CSCs homeostasis. Further, we demonstrated that TG2 protects OC cells from cisplatin-induced apoptosis by regulating NF-κB activity. We proposed a model whereby TGF-β-inducible TG2 modulates EMT, metastasis, CSC homeostasis and chemoresistance in OC. These findings contribute to a better understanding of the mechanisms of OC metastasis modulated by TG2.

No description available.

No description available.

No description available.